Cross-resistance to human cationic antimicrobial peptides and to polymyxins mediated by the plasmid-encoded MCR-1?
- Dobias, Jan Emerging Antibiotic Resistance, Medical and Molecular Microbiology Unit, Department of Medicine, University of Fribourg, Switzerland - INSERM European Unit (IAME, France), University of Fribourg, Fribourg, Switzerland
- Poirel, Laurent Emerging Antibiotic Resistance, Medical and Molecular Microbiology Unit, Department of Medicine, University of Fribourg, Switzerland - INSERM European Unit (IAME, France), University of Fribourg, Fribourg, Switzerland - Swiss National Reference Center for Emerging Antibiotic Resistance (NARA), Fribourg, Switzerland
- Nordmann, Patrice Emerging Antibiotic Resistance, Medical and Molecular Microbiology Unit, Department of Medicine, University of Fribourg, Switzerland - INSERM European Unit (IAME, France), University of Fribourg, Fribourg, Switzerland - Swiss National Reference Center for Emerging Antibiotic Resistance (NARA), Fribourg, Switzerland - Insitute for Microbiology, University of Lausanne and University Hospital Centre, Lausanne, Switzerland
-
23.03.2017
Published in:
- Clinical Microbiology and Infection. - 2017, vol. 23, no. 9, p. 676.e1-676.e5
English
To evaluate whether acquired resistance to cationic antimicrobial peptides (CAMP) group molecules, being normal components of the human immune system, may select co-resistance to antibiotic peptides such as polymyxins, considering they share the same mechanism of action. We aimed to evaluate strains producing the recently identified plasmid-encoded polymyxin resistance determinant MCR-1, which is a phosphoethanolamine transferase that modifies the lipopolysaccharide structure of Gram-negative bacteria.Methods: In-vitro susceptibility studies using human CAMPs, namely cathelicidin LL-37, α-defensin 5 (HD5) and β-defensin 3 (HDB3), towards MCR-1-producing and colistin-resistant Escherichia coli or Klebsiella pneumoniae were performed.Results: Cross-resistance to CAMPs and colistin mediated by MCR-1 or chromosomal mechanisms was neither observed in E. coli nor in K. pneumoniae.Conclusion: Therefore, the future therapeutic development of human CAMPs may likely not be impeded by the spread of MCR-1 plasmid-mediated resistance to polymyxins, at least in E. coli.
- Faculty
- Faculté des sciences et de médecine
- Department
- Médecine 3ème année
- Language
-
- English
- Classification
- Biological sciences
- License
- License undefined
- Identifiers
-
- RERO DOC 288693
- DOI 10.1016/j.cmi.2017.03.015
- Persistent URL
- https://folia.unifr.ch/unifr/documents/305495
Statistics
Document views: 31
File downloads:
- nor_crh.pdf: 42